Impaired beta-cell function in lean normotolerant former gestational diabetic women
- PMID: 16403006
- DOI: 10.1111/j.1365-2362.2006.01587.x
Impaired beta-cell function in lean normotolerant former gestational diabetic women
Abstract
Background: Former gestational diabetes (fGDM) constitutes a risk condition for the development of Type 2 diabetes. Former gestational diabetes is often characterized by obesity and hyperglycaemia, which may be concomitant and independent risk factors.
Materials and methods: To assess insulin sensitivity and beta-cell function in fGDM uncomplicated by obesity and hyperglycaemia, we studied 24 lean fGDM women and 23 control women matched for age (30.7 +/- 0.7 years, whole cohort), body mass index (22.2 +/- 0.3 kg m(-2)), and indistinguishable for plasma glucose both at fasting and at 120 min. Several insulin sensitivity and beta-cell function indices were computed: homeostasis model assessment insulin resistance index (HOMA-R), insulin sensitivity index derived from an oral glucose tolerance test (OGIS), insulinogenic index, other empirical indices of insulin secretion and beta-cell function, and indices obtained using a beta-cell model.
Results: Though the majority of indices, and in particular insulin sensitivity (HOMA-R: 1.35 +/- 0.13 vs. 1.65 +/- 0.14; OGIS: 492.7 +/- 6.3 vs. 496.4 +/- 9.4 mL min(-1) m(-2)), were not significantly different in the two groups, the beta-cell glucose sensitivity obtained by modelling analysis was lower in fGDM (108 +/- 14 vs. 165 +/- 22 pmol min(-1) m(-2) mM(-1), P = 0.031).
Conclusions: Impairment of beta-cell glucose sensitivity may be an intrinsic risk factor in fGDM independently of obesity and hyperglycaemia. Furthermore, we have shown that modelling analysis, in contrast to the empirical parameters, may be able to detect early beta-cell alterations in fGDM women.
Similar articles
-
Value of the intravenous and oral glucose tolerance tests for detecting subtle impairments in insulin sensitivity and beta-cell function in former gestational diabetes.Clin Endocrinol (Oxf). 2008 Aug;69(2):237-43. doi: 10.1111/j.1365-2265.2008.03178.x. Epub 2008 Jan 10. Clin Endocrinol (Oxf). 2008. PMID: 18194489 Clinical Trial.
-
[Replacement of insulin by fasting C-peptide in modified homeostasis model assessment to evaluate insulin resistance and islet beta cell function].Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2004 Aug;29(4):419-23. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2004. PMID: 16134594 Chinese.
-
[Effects of severe hyperglycaemia in pregnancy and early overfeeding on islet development and insulin resistance].Zhonghua Fu Chan Ke Za Zhi. 2010 Sep;45(9):658-63. Zhonghua Fu Chan Ke Za Zhi. 2010. PMID: 21092544 Chinese.
-
Application of structural model of glucose-insulin relations to assess beta-cell function and insulin sensitivity.Horm Metab Res Suppl. 1990;24:66-71. Horm Metab Res Suppl. 1990. PMID: 2272629 Review.
-
Obesity, body fat distribution, insulin sensitivity and Islet beta-cell function as explanations for metabolic diversity.J Nutr. 2001 Feb;131(2):354S-60S. doi: 10.1093/jn/131.2.354S. J Nutr. 2001. PMID: 11160560 Review.
Cited by
-
The heritability of beta cell function parameters in a mixed meal test design.Diabetologia. 2011 May;54(5):1043-51. doi: 10.1007/s00125-011-2060-5. Epub 2011 Feb 11. Diabetologia. 2011. PMID: 21311857 Free PMC article.
-
A 3-year follow-up study of β-cell function in patients with early-onset type 2 diabetes.Exp Ther Med. 2016 Aug;12(2):1097-1102. doi: 10.3892/etm.2016.3394. Epub 2016 May 26. Exp Ther Med. 2016. PMID: 27446326 Free PMC article.
-
Glucokinase, the pancreatic glucose sensor, is not the gut glucose sensor.Diabetologia. 2009 Jan;52(1):154-9. doi: 10.1007/s00125-008-1183-9. Epub 2008 Oct 31. Diabetologia. 2009. PMID: 18974968
-
Correlation between blood activin levels and clinical parameters of type 2 diabetes.Exp Diabetes Res. 2012;2012:410579. doi: 10.1155/2012/410579. Epub 2012 Dec 16. Exp Diabetes Res. 2012. PMID: 23304117 Free PMC article.
-
Acute Changes in Non-esterified Fatty Acids in Patients with Type 2 Diabetes Receiving Bariatric Surgery.Obes Surg. 2017 Mar;27(3):649-656. doi: 10.1007/s11695-016-2323-9. Obes Surg. 2017. PMID: 27530911 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous